Overview
Low-grade endometrial stromal sarcoma (LG-ESS) is a rare subtype of uterine sarcoma characterized by its slow growth and typically indolent behavior. Despite its relatively benign clinical course compared to high-grade sarcomas, LG-ESS requires careful management due to the potential for local recurrence and, in some cases, distant metastasis. Diagnosis often relies on histopathological examination following imaging studies, while management strategies focus on balancing surgical intervention with preservation of reproductive function when possible. This guideline synthesizes evidence from recent studies to provide clinicians with a comprehensive approach to diagnosing, managing, and monitoring patients with LG-ESS.
Diagnosis
Diagnosing LG-ESS involves a combination of clinical presentation, imaging, and definitive histopathological evaluation. Postmenopausal bleeding, abnormal uterine bleeding, and pelvic pain are common presenting symptoms, necessitating thorough evaluation. Imaging modalities such as transvaginal ultrasound (TVUS) and magnetic resonance imaging (MRI) play crucial roles in identifying uterine masses and assessing their characteristics. However, definitive diagnosis hinges on tissue sampling through endometrial biopsy or surgical procedures like hysterectomy or myomectomy.
In postmenopausal women, the choice of biopsy technique can significantly impact patient comfort and diagnostic yield. A multicenter randomized trial [PMID:33686708] demonstrated that snake and alligator forceps are preferable over spoon forceps for endometrial biopsies. These forceps offer advantages such as lower pain levels, higher operator satisfaction, and the ability to obtain wider biopsy samples, which can be particularly beneficial in ensuring adequate tissue for histopathological analysis. Clinicians should consider these forceps as the first choice for biopsy procedures in this patient population to optimize both diagnostic accuracy and patient experience.
Management
The management of LG-ESS aims to achieve complete resection while minimizing morbidity and preserving quality of life. Surgical options range from conservative approaches like hysteroscopic resection to more radical procedures such as hysterectomy, depending on tumor characteristics and patient factors.
Surgical Techniques
For patients with submucous leiomyomas or similar uterine masses that may coexist with LG-ESS, hysteroscopic morcellation (HM) emerges as a conservative and minimally invasive intervention [PMID:34902749]. This technique is recommended for type 0 leiomyomas due to its faster procedure time and reduced learning curve compared to resectoscopy alone. However, in cases involving LG-ESS, the primary goal is complete tumor resection, often necessitating more extensive surgical approaches.
Evaluation of the uterus through imaging modalities such as saline infusion sonohysterography (SIS) and combined assessment by transvaginal ultrasound (TVUS) and diagnostic hysteroscopy is crucial for planning surgical interventions [PMID:34902749]. These assessments help in delineating tumor extent and guiding the choice between less invasive and more definitive surgical options. The STEPW classification system, which evaluates submucosal leiomyomas based on size, location, and number, is recommended to predict complex surgeries, incomplete removal, prolonged operative times, and major complications [PMID:34902749]. This system aids in risk stratification and surgical planning, ensuring that patients are appropriately counseled regarding potential outcomes.
Minimally Invasive Surgery vs. Open Surgery
In the context of advanced endometrial carcinoma (EC) with stage ≥ II and lower uterine segment involvement (LUSI), the role of minimally invasive surgery (MIS) versus laparotomy remains nuanced. A study [PMID:34800816] indicated that MIS was associated with higher locoregional recurrence rates compared to laparotomy, although overall survival outcomes were comparable between the two approaches. This suggests that while MIS offers benefits in terms of reduced postoperative pain and faster recovery, clinicians must weigh these advantages against the potential for increased recurrence risk, particularly in high-risk subgroups. For LG-ESS, where the risk profile may differ, individualized decision-making based on tumor stage, patient preference, and surgeon expertise is essential.
Fluid Management During Surgery
Fluid management during surgical procedures such as bipolar myomectomy is critical, especially in patients with varying degrees of comorbidities. A fluid deficit of up to 1000 mL is generally considered safe for bipolar myomectomy using saline solution in healthy women of reproductive age [PMID:34902749]. However, for elderly patients or those with comorbidities, a more conservative approach with a lower fluid threshold (750 mL) is advised to mitigate risks associated with fluid overload or electrolyte imbalances [PMID:34902749]. Clinicians should tailor fluid management strategies based on individual patient factors to ensure optimal perioperative outcomes.
Complications
The management of LG-ESS carries inherent risks, with potential complications ranging from surgical site issues to systemic effects. One notable complication highlighted in the literature is the increased risk of locoregional recurrence observed in patients undergoing minimally invasive surgery compared to open surgery [PMID:34800816]. This finding underscores the importance of meticulous surgical technique and thorough oncologic clearance to minimize recurrence risk. Additionally, fluid management during procedures like bipolar myomectomy must be carefully monitored to avoid complications such as hyponatremia or fluid overload, particularly in vulnerable patient populations [PMID:34902749].
Prognosis & Follow-Up
Despite the higher locoregional recurrence rates observed in patients undergoing MIS for advanced EC with LUSI, overall survival and progression-free survival rates remain comparable between MIS and laparotomy groups [PMID:34800816]. This suggests that while MIS may not offer a survival advantage, it can still be a viable option for LG-ESS, especially when considering patient-specific factors such as age, comorbidities, and preference for less invasive procedures.
Post-treatment follow-up is critical for monitoring disease recurrence and managing potential late effects. Regular imaging studies, including pelvic ultrasounds and MRI, combined with clinical assessments, are essential. Additionally, serum tumor markers, although not routinely used for LG-ESS, may be considered in specific cases where recurrence is suspected. Long-term surveillance should be individualized based on initial tumor characteristics and surgical outcomes, ensuring that any signs of recurrence are detected early to allow timely intervention.
In clinical practice, a multidisciplinary approach involving gynecologic oncologists, radiologists, and pathologists is recommended to optimize patient care and outcomes for those diagnosed with LG-ESS. Regular multidisciplinary team meetings can facilitate comprehensive patient management and ensure that evidence-based practices are consistently applied.
References
1 Loddo A, Djokovic D, Drizi A, De Vree BP, Sedrati A, van Herendael BJ. Hysteroscopic myomectomy: The guidelines of the International Society for Gynecologic Endoscopy (ISGE). European journal of obstetrics, gynecology, and reproductive biology 2022. link 2 Perri T, Levin G, Helpman L, Eitan R, Vaknin Z, Lavie O et al.. Minimally invasive approach in endometrial cancer with lower uterine segment involvement in stage ≥ II: A retrospective study. European journal of obstetrics, gynecology, and reproductive biology 2022. link 3 Vitale SG, Laganà AS, Caruso S, Garzon S, Vecchio GM, La Rosa VL et al.. Comparison of three biopsy forceps for hysteroscopic endometrial biopsy in postmenopausal patients (HYGREB-1): A multicenter, single-blind randomized clinical trial. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2021. link